Pharmalundensis AB Sustainability Reports
PharmaLundensis AB is a research-stage biotechnology company that develops drugs designed to bind and excrete heavy metals from the body. Its primary candidate, Phal-501, is targeted for the treatment of severe respiratory diseases such as COPD and chronic bronchitis.
Sector: Manufacturing
Country: Sweden
Exchange: Spotlight Stock Market
ISIN: SE0003359710
18 reports from 2007 to 2024